{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:53:21Z","timestamp":1785545601118,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11926-020-00967-8","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T16:02:59Z","timestamp":1606492979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Something Old, Something New: the ACR Gout Treatment Guideline and Its Evolution from 2012 to 2020"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0436-4093","authenticated-orcid":false,"given":"Rebecca E.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-1542","authenticated-orcid":false,"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4152-0232","authenticated-orcid":false,"given":"Michael","family":"Toprover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"issue":"6","key":"967_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheum. 2019;71(6):991\u20139.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"967_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"\u2022\u2022 FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Rheum. 2020;72(6):879\u201395. This study provides the first updated ACR recommendations for gout treatment since 2012 and forms the basis for the current manuscript.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"967_CR3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"967_CR4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res"},{"key":"967_CR5","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND\/UCLA Appropriateness Method User\u2019s Manual. 1700 Main Street, P.O. Box 2138, Santa Monica, CA 90407-2138 1200 South Hayes Street, Arlington, VA 22202-5050: RAND; 2001. 109 p."},{"issue":"6","key":"967_CR6","doi-asserted-by":"publisher","first-page":"e027445","DOI":"10.1136\/bmjopen-2018-027445","volume":"9","author":"BS Alper","year":"2019","unstructured":"Alper BS, Oettgen P, Kunnamo I, Iorio A, Ansari MT, Murad MH, et al. Defining certainty of net benefit: a GRADE concept paper. BMJ Open. 2019;9(6):e027445.","journal-title":"BMJ Open"},{"issue":"7650","key":"967_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ."},{"key":"967_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","volume":"87","author":"M Hultcrantz","year":"2017","unstructured":"Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4\u201313.","journal-title":"J Clin Epidemiol"},{"key":"967_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2019.02.003","volume":"111","author":"HJ Schunemann","year":"2019","unstructured":"Schunemann HJ, Mustafa RA, Brozek J, Santesso N, Bossuyt PM, Steingart KR, et al. GRADE guidelines: 22. The GRADE approach for tests and strategies-from test accuracy to patient-important outcomes and recommendations. J Clin Epidemiol. 2019;111:69\u201382.","journal-title":"J Clin Epidemiol"},{"key":"967_CR10","doi-asserted-by":"crossref","unstructured":"Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O'Hanlon CE, Tariq A, Okunogbe A, Han D, Shanman R. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(1):37\u201351.","DOI":"10.7326\/M16-0461"},{"issue":"1","key":"967_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"\u2022 Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58\u201368. This guideline for clinical recommendations on the management of gout was developed by the American College of Physicians.","journal-title":"Ann Intern Med"},{"issue":"1","key":"967_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"967_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200\u20131210. This study compared, in patients with cardiovascular disease and gout, the use of febuxostat versus allopurinol. Based upon cardiovascular safety, allopurinol is preferred since febuxostat use resulted in higher rates of major adverse cardiovascular events.","DOI":"10.1056\/NEJMoa1710895"},{"key":"967_CR14","unstructured":"Administration UFaD. FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat) [Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat. Accessed 13 Aug 2020."},{"key":"967_CR15","doi-asserted-by":"crossref","unstructured":"Lipsky PE, Edwards NL, Fields TR, Keenan RT, Mandell BF, Schlesinger N. Response to the 2020 American College of Rheumatology Guideline for the Management of Gout: Comment on the Article by FitzGerald et al. Arthritis Care Res (Hoboken). 2020;72(10):1506\u20131507.","DOI":"10.1002\/acr.24379"},{"issue":"3","key":"967_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.40381","volume":"70","author":"AL Gaffo","year":"2018","unstructured":"Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Brief report: validation of a definition of flare in patients with established gout. Arthritis Rheum. 2018;70(3):462\u20137.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"967_CR17","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","volume":"78","author":"D Bursill","year":"2019","unstructured":"Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592\u2013600.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"967_CR18","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018\u201329.","journal-title":"Nucleosides Nucleotides Nucleic Acids"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00967-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-020-00967-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00967-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:14:30Z","timestamp":1612818870000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-020-00967-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s11926-020-00967-8","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"15 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RC\u2014nothing to disclose; MT\u2014nothing to disclose; MHP\u2014investigator-initiated research grants from Horizon Therapeutics and Hikma Pharmaceuticals; consultancies with Swedish Orphan Biovitrum and Horizon Therapeutics. MHP is supported in part by NIH grant 1UL1 TR001445 from the National Center for Advancing Translational Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This work is original and has not been published elsewhere in any form, nor submitted to any other journal. As a review article, no additional ethics approvals are required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors consent to the publication of the submitted manuscript. No other consent is applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}],"article-number":"4"}}